These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10942175)

  • 41. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord.
    Ebert B; Andersen S; Krogsgaard-Larsen P
    Neurosci Lett; 1995 Mar; 187(3):165-8. PubMed ID: 7624018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.
    Magenau JM; Braun T; Reddy P; Parkin B; Pawarode A; Mineishi S; Choi S; Levine J; Li Y; Yanik G; Kitko C; Churay T; Frame D; Riwes MM; Harris A; Bixby D; Couriel DR; Goldstein SC
    Ann Hematol; 2015 Jun; 94(6):1033-41. PubMed ID: 25784222
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ketobemidone plus (RS)-3-dimethylamino-1,1-diphenylbut-1-ene (A29) is more potent at NMDA receptors than ketobemidone alone: evidence for A29 as a non-competitive NMDA receptor antagonist.
    Ebert B; Thorkildsen C; Andersen S
    Pharmacol Toxicol; 1998 Mar; 82(3):157-60. PubMed ID: 9553996
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Which dose of busulfan is best?
    Johnson-Davis KL; McMillin GA; Juenke JM; Ford CD; Petersen FB
    Clin Chem; 2010 Jul; 56(7):1061-4. PubMed ID: 20585045
    [No Abstract]   [Full Text] [Related]  

  • 45. Therapeutic drug monitoring of busulfan in transplantation.
    Russell JA; Kangarloo SB
    Curr Pharm Des; 2008; 14(20):1936-49. PubMed ID: 18691105
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Kharfan-Dabaja MA; Labopin M; Bazarbachi A; Socie G; Kroeger N; Blaise D; Veelken H; Bermudez A; Or R; Lioure B; Beelen D; Fegueux N; Hamladji RM; Nagler A; Mohty M
    Leuk Res; 2015 Sep; 39(9):933-7. PubMed ID: 26003666
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
    Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
    Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
    [No Abstract]   [Full Text] [Related]  

  • 48. Evaluation of Limited Sampling Methods for Oral Busulfan Pharmacokinetic Monitoring in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation.
    Bouchard P; Bilodeau S; Alain K; Vadnais B; Franco M; Turgeon J; Michaud V
    Ther Drug Monit; 2016 Jun; 38(3):414-8. PubMed ID: 26829598
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Zwaveling J; den Hartigh J; Lankester AC; Guchelaar HJ; Egeler RM; Bredius RG
    Anticancer Drugs; 2006 Oct; 17(9):1099-105. PubMed ID: 17001185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fludarabine-IV busulfan, dose-intensity and progression-free survival: Are we finally finding the way to reach a consensus opinion?: Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the acute leukemia working party of the European group for blood and marrow transplantation.
    Andersson BS
    Leuk Res; 2016 Feb; 41():5-6. PubMed ID: 26733443
    [No Abstract]   [Full Text] [Related]  

  • 51. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.
    Almog S; Kurnik D; Shimoni A; Loebstein R; Hassoun E; Gopher A; Halkin H; Nagler A
    Biol Blood Marrow Transplant; 2011 Jan; 17(1):117-23. PubMed ID: 20601034
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
    Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
    Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?
    Clemmons AB; Evans S; DeRemer DL; Awan FT
    J Oncol Pharm Pract; 2015 Dec; 21(6):425-32. PubMed ID: 24986792
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration.
    Anderson P; Arnér S; Bondesson U; Boréus LO; Hartvig P
    Eur J Clin Pharmacol; 1981 Feb; 19(3):217-23. PubMed ID: 7215421
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft.
    Hare CB; Elion GB; Colvin OM; Ali-Osman F; Griffith OW; Petros WP; Keir S; Marcelli SL; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 1997; 40(5):409-14. PubMed ID: 9272117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel drug interaction between busulfan and blinatumomab.
    Sweiss K; Quigley JG; Oh A; Lee J; Ye R; Rondelli D; Patel P
    J Oncol Pharm Pract; 2019 Jan; 25(1):226-228. PubMed ID: 28857712
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histamine release from human basophils and isolated rat mast cells induced by ketobemidone, pethidine and the spasmolytic A29.
    Grosman N
    Acta Pharmacol Toxicol (Copenh); 1982 Jan; 50(1):78-80. PubMed ID: 6175179
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children.
    Lundeberg S; Stephanson N; Lafolie P; Olsson GL; Stiller CO; Eksborg S
    Acta Anaesthesiol Scand; 2010 Apr; 54(4):435-41. PubMed ID: 19839946
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
    Lee JW; Kang HJ; Lee SH; Yu KS; Kim NH; Yuk YJ; Jang MK; Han EJ; Kim H; Song SH; Park KD; Shin HY; Jang IJ; Ahn HS
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):944-50. PubMed ID: 22155501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.